BioCentury
ARTICLE | Company News

Origen Therapeutics Inc., U.S. Department of Commerce infectious, cancer, antibodies news

October 8, 2007 7:00 AM UTC

Origen received a $2 million, three-year contract from the DoC's National Institute of Standards and Technology division to develop a method for discovering and producing human polyclonal antibodies f...